2-deoxy-β-D-lyxo-hexopyranose | 14215-78-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-deoxy-β-D-lyxo-hexopyranose
• 英文别名: 2-deoxygalactose (β-pyranose)；2-deoxy-β-D-galactose；2-deoxy-D-galactose；2-deoxy-β-D-galactopyranose；2-deoxy-β-D-talopyranose；β-D-lyx-dHexp；2-Deoxy-beta-D-lyxo-hexopyranose；(2R,4R,5R,6R)-6-(hydroxymethyl)oxane-2,4,5-triol
• CAS: 14215-78-2
• 化学式: C₆H₁₂O₅
• 分子量: 164.158
• InChiKey: PMMURAAUARKVCB-KVTDHHQDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  90.2
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• [EN] NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES<br/>[FR] NOUVEAUX CONJUGUÉS CONTENANT TÉTRAGALNAC ET PEPTIDE ET PROCÉDÉS POUR L'ADMINISTRATION D'OLIGONUCLÉOTIDES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013166155A1

  公开（公告）日：2013-11-07

  Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

  本文揭示了一种模块化组合物，包括1）寡核苷酸；2）一个或多个符合式(I)的四聚GalNAc配体，可以相同也可以不同；可选地，3）一个或多个连接剂，可以相同也可以不同；4）从表3中独立选择的一个或多个肽，可以相同也可以不同；以及可选地，5）一个或多个靶向配体、增溶剂、药代动力学增强剂、脂质和/或掩蔽剂。
• [EN] NOVEL TETRAGALNAC CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES<br/>[FR] NOUVEAUX CONJUGUÉS CONTENANT TÉTRAGALNAC ET PROCÉDÉS POUR L'ADMINISTRATION D'OLIGONUCLÉOTIDES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013166121A1

  公开（公告）日：2013-11-07

  Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

  本文揭示了一种模块化组合物，包括1）寡核苷酸；2）一个或多个Formula (I)的四聚GalNAc配体，可能相同或不同；可选地，3）一个或多个连接剂，可能相同或不同；以及可选地，4）一个或多个靶向配体、增溶剂、药代动力学增强剂、脂质和/或掩蔽剂。
• [EN] OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE C-GLYCOSIDES OLIGOSACCHARIDIQUES
  申请人：OKINAWA INST SCIENCE & TECH SCHOOL CORP

  公开号：WO2019182087A1

  公开（公告）日：2019-09-26

  The present invention provides a novel process for preparing an oligosaccharide C-glycoside derivative of formula I, comprising reacting a compound of formula II with compound of formula III in the presence of at least one primary or secondary amine and at least one additive [in the formulae, the substituents are as defined herein], and novel oligosaccharide C-glycoside derivatives that can be prepared using the process.

  本发明提供了一种制备公式I的寡糖C-糖苷衍生物的新型方法，包括在至少一种一级或二级胺和至少一种添加剂的存在下，将公式II的化合物与公式III的化合物反应[在公式中，取代基如在此定义]，以及可以使用该方法制备的新型寡糖C-糖苷衍生物。
• [EN] DISULFIDE MASKED PRODRUG COMPOSITIONS AND METHODS<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT MASQUÉ À BASE DE DISULFURE ET MÉTHODES ASSOCIÉES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014088920A1

  公开（公告）日：2014-06-12

  The present invention relates to disulfide masked prodrug compounds, compositions and methods that are amenable to bioactivation by a reducing agent such as glutathione. Such disulfide based compounds, compositions, and methods can be useful, for example, in providing novel prodrugs for use as therapeutics. The prodrug compounds, compositions and methods of the invention feature a conformationally restricted disulfide phosphotriester moiety to mask anionic charge. The conformationally restricted disulfide phosphotriester moiety can also serve as a scaffold to attach a helper molecule, such as targeting moieties, immunnosuppression moieties, solubility enhancing moieties etc.

  本发明涉及掩蔽二硫键的前药化合物、组合物和方法，这些化合物、组合物和方法可被还原剂如谷胱甘肽生物活化。这些基于二硫键的化合物、组合物和方法可以用作治疗的新型前药。本发明的前药化合物、组合物和方法具有构象限制的二硫键磷酸三酯基团来掩盖阴离子电荷。这种构象限制的二硫键磷酸三酯基团也可以作为一个支架来连接辅助分子，例如靶向分子、免疫抑制分子、增溶分子等。
• [EN] GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY<br/>[FR] COMPOSITIONS DE GALNAC POUR AMÉLIORER LA BIODISPONIBILITÉ D'ARNSI
  申请人：EMPIRICO INC

  公开号：WO2022140365A1

  公开（公告）日：2022-06-30

  Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.

  本文提供了一种包含GalNAc基团的组合物，可以与寡核苷酸共价结合。该寡核苷酸可以是小干扰RNA或反义寡核苷酸。本文还提供了包括将该组合物用于治疗的方法，该方法包括向受试者施用该组合物。